Inspire Medical Systems (NYSE:INSP) Announces Quarterly Earnings Results, Beats Estimates By $0.33 EPS

Inspire Medical Systems (NYSE:INSP - Get Free Report) announced its quarterly earnings results on Monday. The company reported $0.10 EPS for the quarter, topping analysts' consensus estimates of ($0.23) by $0.33, Zacks reports. Inspire Medical Systems had a return on equity of 8.19% and a net margin of 6.67%. Inspire Medical Systems updated its FY 2025 guidance to 2.200-2.300 EPS.

Inspire Medical Systems Price Performance

Shares of NYSE:INSP traded down $0.14 during trading on Monday, hitting $159.67. The company's stock had a trading volume of 698,716 shares, compared to its average volume of 522,462. The firm has a market cap of $4.75 billion, a price-to-earnings ratio of 92.29, a P/E/G ratio of 2.86 and a beta of 1.39. The company has a 50-day moving average of $160.65 and a 200-day moving average of $179.55. Inspire Medical Systems has a 12 month low of $123.00 and a 12 month high of $256.11.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Truist Financial cut their price target on shares of Inspire Medical Systems from $250.00 to $235.00 and set a "buy" rating on the stock in a report on Tuesday, February 11th. Piper Sandler lowered their price target on Inspire Medical Systems from $260.00 to $233.00 and set an "overweight" rating for the company in a research report on Monday, February 10th. Wells Fargo & Company reduced their target price on Inspire Medical Systems from $198.00 to $195.00 and set an "equal weight" rating on the stock in a research note on Tuesday, February 11th. KeyCorp dropped their target price on shares of Inspire Medical Systems from $234.00 to $216.00 and set an "overweight" rating for the company in a research report on Monday, April 21st. Finally, Royal Bank of Canada reduced their price target on shares of Inspire Medical Systems from $260.00 to $215.00 and set an "outperform" rating on the stock in a research report on Tuesday, April 15th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, Inspire Medical Systems presently has an average rating of "Moderate Buy" and an average price target of $218.90.

Insider Activity at Inspire Medical Systems

In related news, insider Randy Ban sold 25,584 shares of the business's stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $183.50, for a total value of $4,694,664.00. Following the transaction, the insider now directly owns 7,259 shares of the company's stock, valued at approximately $1,332,026.50. The trade was a 77.90 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CTO John Rondoni sold 583 shares of the stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $170.49, for a total transaction of $99,395.67. Following the transaction, the chief technology officer now directly owns 10,424 shares of the company's stock, valued at $1,777,187.76. This trade represents a 5.30 % decrease in their position. The disclosure for this sale can be found here. 4.10% of the stock is currently owned by company insiders.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.